In vitro Inhibitory Activity of Tumor Necrosis Factor Alpha and lnterleukin-2 of Human Immunoglobulin Preparations

International Archives of Allergy and Immunology

Volumn 114, Issue 4, 1997, Pages 323-328

  Menezes, M C S ^a   Benard, G ^a   Sato, M N ^a   Hong, M A ^a   Duarte, A J S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Autoantibodies; Cytokines; Human intravenous; Immunoglobulin preparations; Interleukin 2; Tumor necrosis factor and

Indexed keywords

HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SECRETION; CELL STRAIN L 929; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030732234     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237689     Document Type: Article

References (18)

1. Ronda N, Hurez V, Kazatchkine MD: Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory disease, Vox Sang 1993;64:65-72.
2. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune disease, Clin Exp Immunol 1991:86:192-198.
3. Rosen FS: Putative mechanisms of the effects of intravenous vs, globulin, Clin Immunol Im-munopathol 1993;67:541-543.
4. Rossi F, Dietrich G, Kazatchkine MD: Anti-idi-otypes against autoantibodies in normal immunoglobulins: Evidence of network regulation of human autoimmune responses, Immunol Rev 1989;110:135-149.
5. llober D, Haque A, Wattre P, Beaucaire G, Mounton Y, Capron A: Production of tumour necrosis factor-alpha (TNF-ct) and interleukin-1 (IL-1) in patients with AIDS, Enhanced level of TNF'-a is related to a higher cytotoxic activity, Clin Exp Immunol 1989;78:329-333.
6. Fomgaard A, Svenson M, Bendtzen K: Autoantibodies to tumour necrosis in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections, Scand J Immunol 1989:30:219-223.
7. Bandtzen K, Svenson M, Jonsson V, Hippe E: Autoantibodies to cytokines - Friends or foes? Immunol Today 1990; 11:167-169.
8. Flick DA, Gifford GE: Comparison of in vitro cell cytotoxic assays for tumor necrosis factor, J Immunol Methods 1984;68:167-175.
9. Palladino MA, Obata Y, Stockert E, Oettgen HF: Characterization of interleukin-2-dcpend-ent cytotoxic T-cell clones: Specificity, cell surface phenotype, and susceptibility to blocking by Lyt antisera, Cancer Res 1983;43:572-576.
10. Bocci V, Carraro F, Zculi M, Naldini A, Cala-bresi F: The lymphatic route, VIII, Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patients, Biotherapy 1993;6:73-77.
11. Toyoda M, Zhang X, Petrosian A, Galcra OA, Wang SJ, Jordan SC: Modulation of immunoglobulin production and cytokinc mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin, Clin Exp Immunol 1994;14:178-189.
12. Avramcas S: Natural autoantibodies: From ‘horror autotoxicus' to ‘gnothi scauton', Immunol Today 1991;12:154-159.
13. Bost KL’ Hahn BH, Saag MS, Shaw GM, Wei-gent DA, Blalock JE: Individual infected with HIV possess antibodies against IL-2, Immunology 1988:65:611-615.
14. Shimozato T, Iwata M, Kawada H, Tamura N: Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3’5'-monophosphatc levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production, Immunology 1991;72:497-501.
15. Gclfand EW: Benefit of replacement therapy with high dose intravenous gammaglobulin in patients with hypogammaglobulinemia and chronic sinopulmonary disease: in Koch C (ed): Clinical Use of Intravenous Immunoglobulin (IVIG), Copenhagen, FADL, 1988.
16. Roiffman CM, Gelfand F.W: Replacement therapy with high dose intravenous gamma-globu-lin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia, Pediatr Infect Dis J 1988;7:92-97.
17. Achiron A, Margalit R, Hershkoviz R, Marko-vits D, Rcshhef T, Melamed E, Cohen 1R, Lidcr O: Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease, Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion, J Clin Invest 1994;93:600-605.
18. Muscat C, Bertotto A, Ercolani R, Bistoni O, Agea E, Cesarotti M, Fiorucci G, Spinozzi F, Gerli R: Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: Effects on disease activity and serum cytokines, Ann Rheum Dis 1995:54:382-385.